Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
Robert M. Cox, Josef D. Wolf, Richard K. Plemper
Nature Microbiology (2020) Vol. 6, Iss. 1, pp. 11-18
Open Access | Times Cited: 383

Showing 1-25 of 383 citing articles:

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 6, pp. 509-520
Open Access | Times Cited: 1638
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
Florian Kabinger, Carina Stiller, Jana Schmitzová, et al.
Nature Structural & Molecular Biology (2021) Vol. 28, Iss. 9, pp. 740-746
Open Access | Times Cited: 601
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl, Lisa E. Gralinski, Claire Johnson, et al.
Nature (2021) Vol. 591, Iss. 7850, pp. 451-457
Open Access | Times Cited: 365
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
Wendy Painter, Wayne Holman, Jim Bush, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 65, Iss. 5
Open Access | Times Cited: 351
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Christopher Butler, Richard Hobbs, Oghenekome Gbinigie, et al.
The Lancet (2022) Vol. 401, Iss. 10373, pp. 281-293
Open Access | Times Cited: 316
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
William A. Fischer, Joseph J. Eron, Wayne Holman, et al.
Science Translational Medicine (2021) Vol. 14, Iss. 628
Open Access | Times Cited: 297
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
Calvin J. Gordon, Egor P. Tchesnokov, Raymond F. Schinazi, et al.
Journal of Biological Chemistry (2021) Vol. 297, Iss. 1, pp. 100770-100770
Open Access | Times Cited: 259
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics
Lauren Forchette, William Sebastian, Tuoen Liu
Current Medical Science (2021) Vol. 41, Iss. 6, pp. 1037-1051
Open Access | Times Cited: 225
Molnupiravir in COVID-19: A systematic review of literature
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2021) Vol. 15, Iss. 6, pp. 102329-102329
Open Access | Times Cited: 212
Molnupiravir, an Oral Antiviral Treatment for COVID-19
William A. Fischer, Joseph J. Eron, Wayne Holman, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 209
Wuhan to World: The COVID-19 Pandemic
Ashok Kumar, Rita Gill Singh, Jaskaran Kaur, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 201
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
Rory D. de Vries, Katharina S. Schmitz, Francesca T. Bovier, et al.
Science (2021) Vol. 371, Iss. 6536, pp. 1379-1382
Open Access | Times Cited: 194
Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
D. Schultz, Robert M. Johnson, Kasirajan Ayyanathan, et al.
Nature (2022) Vol. 604, Iss. 7904, pp. 134-140
Open Access | Times Cited: 169
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
George R. Painter, Michael G. Natchus, Oren J. Cohen, et al.
Current Opinion in Virology (2021) Vol. 50, pp. 17-22
Open Access | Times Cited: 156
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
Kyle Rosenke, Frederick Hansen, Benjamin Schwarz, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 147
Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19
John A. McIntosh, Tamas Benkovics, Steven M. Silverman, et al.
ACS Central Science (2021) Vol. 7, Iss. 12, pp. 1980-1985
Open Access | Times Cited: 134
Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses
Yue Ma, Estrella Frutos-Beltrán, Dongwei Kang, et al.
Chemical Society Reviews (2021) Vol. 50, Iss. 7, pp. 4514-4540
Open Access | Times Cited: 132
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
Rana Abdelnabi, Caroline S. Foo, Suzanne J. F. Kaptein, et al.
EBioMedicine (2021) Vol. 72, pp. 103595-103595
Open Access | Times Cited: 130
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
Koen Vandyck, Jérôme Deval
Current Opinion in Virology (2021) Vol. 49, pp. 36-40
Open Access | Times Cited: 129
Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
Rana Abdelnabi, Caroline S. Foo, Steven De Jonghe, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. 5, pp. 749-753
Open Access | Times Cited: 124
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
Chunlong Ma, Zilei Xia, M. Sacco, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 49, pp. 20697-20709
Open Access | Times Cited: 121
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
Haozhou Tan, Yanmei Hu, Prakash D. Jadhav, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7561-7580
Open Access | Times Cited: 118
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
Malina A. Bakowski, Nathan Beutler, Karen C. Wolff, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 112
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Monika Kumari, Ruei‐Min Lu, Mu‐Chun Li, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 111
Page 1 - Next Page

Scroll to top